Kereos, Bristol-Myers Squibb to collaborate in molecular imaging

Mar 2, 2004

Bristol-Myers Squibb Medical Imaging of North Billerica, MA, and Kereos of St. Louis, MO, have entered into agreements for the development and commercialization of molecular imaging agents.

Under the agreement, the companies will work together to develop products for cardiovascular disease and cancer using Kereos’ technology. Bristol-Myers Squibb Medical Imaging has obtained exclusive worldwide rights to develop and commercialize select cardiovascular molecular imaging agents for MRI, according to the company.

Kereos has obtained exclusive worldwide rights to use a family of Bristol-Myers Squibb Medical Imaging targeting molecules to develop and commercialize molecular cancer imaging agents and targeted therapeutics, including KI-001, Kereos’ lead candidate for early MRI detection of tumors, the company said. Financial terms of the agreements were not disclosed.

By AuntMinnie.com staff writers
March 3, 2004
Related Reading

Fujisawa, Bristol-Myers Squibb ink promotion deal, October 21, 2003

DraxImage, Bristol-Meyers Squibb extend partnership, July 2, 2003

AnorMed, Bristol-Myers Squibb link up, December 10, 2002

Bristol-Myers Squibb appoints imaging chief, July 31, 2002

Bristol-Myers-Squibb, Amersham Health share patent rights, November 15, 2001

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$